Journal of diabetes and its complications最新文献

英文中文

Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy 胰高血糖素样肽-1受体激动剂与二肽基肽酶4抑制剂在晚期慢性肾病和终末期肾病中的疗效和治疗持久性

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2025-01-01 DOI: 10.1016/j.jdiacomp.2024.108925

F.N.U. Sidra , Shubham Agarwal , Paola Lockhart Pastor , Donglu Xie , Xilong Li , Ildiko Lingvay

Background

Atherosclerotic cardiovascular disease is the leading cause of death in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) or end-stage kidney disease (ESKD). Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) reduce cardiovascular events, improve glycemic control, promote weight loss, and slow progression of nephropathy. Despite these benefits and professional society treatment guidelines recommendations, GLP-1RAs remain under-utilized in people with advanced CKD and ESKD due to tolerability and safety concerns.

Methods

We conducted a retrospective cohort study comparing clinical outcomes and medication use details after initiating GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP-4i) in people with T2D and advanced CKD or ESKD. Eligible patients were identified via electronic health record query with extraction of baseline demographics, vital signs, and laboratory values. A manual chart review was undertaken to confirm eligibility, medication use, and extract a detailed account of all side effects.

Results

A total of 236 eligible patients (149 in the GLP-1RA group and 87 in the DPP-4i group) were identified. The average duration of treatment was 1036 (±909.9) and 1109 (±1090.9) days for GLP-1RA and DPP-4i, respectively. The average percentage weight loss from baseline to 36 months of treatment in the GLP-1RA group was −9.6 % (95 % CI, −11.3 to −7.8) versus −2.4 % (95 % CI, −5.4 to 0.5) in the DPP-4i group (estimated treatment difference (ETD) -7.1 (95 % CI, −10.6 to −3.7) percentage-points, p < 0.001). The change in HbA1c from baseline to 36 months of treatment was significantly greater in the GLP-1RA (−1.0 %) compared with the DPP-4i group (0.2 %) (ETD -1.2 (95 % CI, −2.1 to −0.3) percentage-points, p = 0.04).

Conclusion

In patients with T2D and advanced CKD or ESKD, treatment with GLP-1RAs in a real-world setting had long treatment persistence, and compared to DPP-4is, was associated with greater weight loss and glycemic improvement.

背景：动脉粥样硬化性心血管疾病是2型糖尿病（T2D）和慢性肾脏疾病（CKD）或终末期肾脏疾病（ESKD）患者死亡的主要原因。胰高血糖素样肽-1受体激动剂（GLP-1RA）减少心血管事件，改善血糖控制，促进体重减轻，减缓肾病的进展。尽管有这些益处和专业协会治疗指南的建议，由于耐受性和安全性问题，GLP-1RAs在晚期CKD和ESKD患者中的应用仍然不足。方法：我们进行了一项回顾性队列研究，比较T2D和晚期CKD或ESKD患者在启动GLP-1RA或二肽基肽酶4抑制剂（DPP-4i）后的临床结果和药物使用细节。通过提取基线人口统计学、生命体征和实验室值的电子健康记录查询确定符合条件的患者。进行了手动图表审查，以确认资格，药物使用，并提取所有副作用的详细说明。结果：共确定236例符合条件的患者（GLP-1RA组149例，DPP-4i组87例）。GLP-1RA和DPP-4i的平均治疗时间分别为1036（±909.9）天和1109（±1090.9）天。GLP-1RA组从基线到治疗36个月的平均体重下降百分比为- 9.6% (95% CI, -11.3至-7.8)，而DPP-4i组为- 2.4% (95% CI, -5.4至0.5)(估计治疗差异(ETD) -7.1 （95% CI, -10.6至-3.7）个百分点，p。在T2D和晚期CKD或ESKD患者中，在现实环境中使用GLP-1RAs治疗具有较长的治疗持久性，并且与DPP-4is相比，与更大的体重减轻和血糖改善相关。

{"title":"Glucagon-like Peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: Real world effectiveness and persistence of therapy","authors":"F.N.U. Sidra , Shubham Agarwal , Paola Lockhart Pastor , Donglu Xie , Xilong Li , Ildiko Lingvay","doi":"10.1016/j.jdiacomp.2024.108925","DOIUrl":"10.1016/j.jdiacomp.2024.108925","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic cardiovascular disease is the leading cause of death in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) or end-stage kidney disease (ESKD). Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) reduce cardiovascular events, improve glycemic control, promote weight loss, and slow progression of nephropathy. Despite these benefits and professional society treatment guidelines recommendations, GLP-1RAs remain under-utilized in people with advanced CKD and ESKD due to tolerability and safety concerns.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study comparing clinical outcomes and medication use details after initiating GLP-1RA or dipeptidyl-peptidase 4 inhibitor (DPP-4i) in people with T2D and advanced CKD or ESKD. Eligible patients were identified via electronic health record query with extraction of baseline demographics, vital signs, and laboratory values. A manual chart review was undertaken to confirm eligibility, medication use, and extract a detailed account of all side effects.</div></div><div><h3>Results</h3><div>A total of 236 eligible patients (149 in the GLP-1RA group and 87 in the DPP-4i group) were identified. The average duration of treatment was 1036 (±909.9) and 1109 (±1090.9) days for GLP-1RA and DPP-4i, respectively. The average percentage weight loss from baseline to 36 months of treatment in the GLP-1RA group was −9.6 % (95 % CI, −11.3 to −7.8) versus −2.4 % (95 % CI, −5.4 to 0.5) in the DPP-4i group (estimated treatment difference (ETD) -7.1 (95 % CI, −10.6 to −3.7) percentage-points, <em>p</em> < 0.001). The change in HbA1c from baseline to 36 months of treatment was significantly greater in the GLP-1RA (−1.0 %) compared with the DPP-4i group (0.2 %) (ETD -1.2 (95 % CI, −2.1 to −0.3) percentage-points, <em>p</em> = 0.04).</div></div><div><h3>Conclusion</h3><div>In patients with T2D and advanced CKD or ESKD, treatment with GLP-1RAs in a real-world setting had long treatment persistence, and compared to DPP-4is, was associated with greater weight loss and glycemic improvement.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108925"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of visit-to-visit glycated hemoglobin variability on diabetes distress and its subscales 就诊间糖化血红蛋白变异对糖尿病窘迫及其亚量表的影响。

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2025-01-01 DOI: 10.1016/j.jdiacomp.2024.108924

So-hyeon Hong , Yongho Jee , Yeon-Ah Sung , Young Sun Hong , Do Kyeong Song , Hyein Jung , Hyejin Lee

Aims

This study aimed to investigate the correlations between glycated hemoglobin (HbA1C) variability and diabetes distress (DD) and its subscales in older patients with type 2 diabetes mellitus.

Methods

The cross-sectional study analyzed 175 patients with type 2 diabetes mellitus, aged ≥60 years, and underwent HbA1C testing at least three times within a 2-year. HbA1C variability was assessed using the coefficient of variation (CV), standard deviation (SD), variability independent of the mean (VIM), and variability score. DD was assessed using a diabetes distress scale (DDS) questionnaire. We analyzed four DDS subscales, including emotional burden (EB), regimen distress (RD), interpersonal distress (ID), and physician distress (PD). Significant DD was defined as a total score ≥ 34.

Results

All four indices of HbA1C variability were positively correlated with DDS (r = 0.19, P = 0.01 in CV; r = 0.19, P = 0.01 in SD; r = 0.19, P = 0.02 in VIM; and r = 0.18, P = 0.02 in variability score). For the DD subscales, only EB showed a significant correlation with HbA1C variability (β = 0.72, SE = 0.35 in CV; β = 0.70, SE = 0.35 in SD; β = 0.66, SE = 0.31 in VIM; and β = 0.77, SE = 0.35 in variability score).

Conclusions

HbA1C variability was independently linked to DD, particularly the EB subscale in older type 2 diabetes patients. This underscores the need for DD screening and intervention in patients with high HbA1C variability, irrespective of their HbA1C levels or depressive symptoms.

目的：本研究旨在探讨老年2型糖尿病患者糖化血红蛋白（HbA1C）变异性与糖尿病窘迫（DD）及其亚量表的相关性。方法：横断面研究分析175例2型糖尿病患者，年龄≥60岁，2年内至少接受3次HbA1C检测。采用变异系数（CV）、标准差（SD）、独立于平均值的变异（VIM）和变异评分来评估HbA1C的变异性。采用糖尿病困扰量表（DDS）问卷对DD进行评估。我们分析了四个DDS分量表，包括情绪负担（EB）、方案困扰（RD）、人际困扰（ID）和医生困扰（PD）。总分≥34分为显著DD。结果：HbA1C变异性4项指标均与DDS呈正相关(r = 0.19, P = 0.01；r = 0.19, P = 0.01；VIM组r = 0.19, P = 0.02；变异评分r = 0.18, P = 0.02)。在DD亚量表中，只有EB与HbA1C变异性有显著相关性(CV中β = 0.72, SE = 0.35；β = 0.70， SD中SE = 0.35；VIM β = 0.66, SE = 0.31；变异性评分β = 0.77, SE = 0.35)。结论：HbA1C变异性与DD独立相关，特别是老年2型糖尿病患者的EB亚量表。这强调了对HbA1C高变异性患者进行DD筛查和干预的必要性，无论其HbA1C水平或抑郁症状如何。

{"title":"Impact of visit-to-visit glycated hemoglobin variability on diabetes distress and its subscales","authors":"So-hyeon Hong , Yongho Jee , Yeon-Ah Sung , Young Sun Hong , Do Kyeong Song , Hyein Jung , Hyejin Lee","doi":"10.1016/j.jdiacomp.2024.108924","DOIUrl":"10.1016/j.jdiacomp.2024.108924","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the correlations between glycated hemoglobin (HbA1C) variability and diabetes distress (DD) and its subscales in older patients with type 2 diabetes mellitus.</div></div><div><h3>Methods</h3><div>The cross-sectional study analyzed 175 patients with type 2 diabetes mellitus, aged ≥60 years, and underwent HbA1C testing at least three times within a 2-year. HbA1C variability was assessed using the coefficient of variation (CV), standard deviation (SD), variability independent of the mean (VIM), and variability score. DD was assessed using a diabetes distress scale (DDS) questionnaire. We analyzed four DDS subscales, including emotional burden (EB), regimen distress (RD), interpersonal distress (ID), and physician distress (PD). Significant DD was defined as a total score ≥ 34.</div></div><div><h3>Results</h3><div>All four indices of HbA1C variability were positively correlated with DDS (<em>r</em> = 0.19, <em>P</em> = 0.01 in CV; <em>r</em> = 0.19, <em>P</em> = 0.01 in SD; <em>r</em> = 0.19, <em>P</em> = 0.02 in VIM; and <em>r</em> = 0.18, <em>P</em> = 0.02 in variability score). For the DD subscales, only EB showed a significant correlation with HbA1C variability (<em>β</em> = 0.72, SE = 0.35 in CV; <em>β</em> = 0.70, SE = 0.35 in SD; <em>β</em> = 0.66, SE = 0.31 in VIM; and <em>β</em> = 0.77, SE = 0.35 in variability score).</div></div><div><h3>Conclusions</h3><div>HbA1C variability was independently linked to DD, particularly the EB subscale in older type 2 diabetes patients. This underscores the need for DD screening and intervention in patients with high HbA1C variability, irrespective of their HbA1C levels or depressive symptoms.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108924"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cambridge risk score, new hyperglycemia, and complications in surgical patients without diabetes 无糖尿病手术患者的剑桥风险评分、新发高血糖和并发症。

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2025-01-01 DOI: 10.1016/j.jdiacomp.2024.108926

Hannah Lee , Phillip J. Hartfield , Abigail Thorgerson , Grant P. Sinson , Marjorie Wang , Carlos E. Mendez

Aims

Our study examined the association between the Cambridge Risk Score (CRS), new hyperglycemia (NH), and complications in patients undergoing elective surgery.

Methods

In this retrospective cross-sectional study, adult surgical patients, without diabetes, with NH (blood glucose ≥140 mg/dL) were identified, and the CRS was calculated. We used univariate regression models to evaluate the relationship between CRS and NH with 30-day readmission, length of stay (LOS), and complications. Models were stratified by surgical specialty (cardiac/vascular, general, orthopedic, neurologic).

Results

Of 10,531 patients in the study, 24 % had NH. After adjusting for covariates, the CRS was associated with increased odds of complications [OR 2.09; 95%CI:1.69, 2.59] and NH [OR 1.95; 95%CI:1.66, 2.29]. NH was associated with increased odds of 30-day readmission [β 1.60; 95%CI:1.31, 1.96], and increased LOS [β 0.64; 95%CI:0.59, 0.68]. When stratified by surgery type, the CRS was associated with increased LOS in neurosurgery, decreased LOS in orthopedics, and increased odds of complications and NH in neurosurgery and orthopedics.

Conclusion

The CRS is associated with NH, complications, and LOS in patients undergoing elective neurosurgery, orthopedic surgery, and general surgery. This suggests that CRS may have potential to help identify surgical patients at high risk for NH and complications.

目的：我们的研究探讨了择期手术患者的剑桥风险评分（CRS）、新发高血糖（NH）和并发症之间的关系。方法：采用回顾性横断面研究方法，选取无糖尿病的成人手术患者，确定NH（血糖≥140 mg/dL），计算CRS。我们使用单变量回归模型来评估CRS和NH与30天再入院、住院时间（LOS）和并发症之间的关系。模型按外科专科（心脏/血管、普通、骨科、神经）分层。结果：在研究的10531例患者中，24%患有NH。调整协变量后，CRS与并发症发生率增加相关[OR 2.09；95%CI:1.69, 2.59]和NH [OR 1.95；95%置信区间:1.66,2.29)。NH与30天再入院几率增加有关[β 1.60；95%CI:1.31, 1.96]，且LOS升高[β 0.64；95%置信区间:0.59,0.68)。当按手术类型分层时，CRS与神经外科的LOS增加，骨科的LOS降低，神经外科和骨科的并发症和NH的发生率增加有关。结论：择期神经外科、骨科和普外科患者的CRS与NH、并发症和LOS相关。这表明CRS可能有助于识别NH和并发症高风险的手术患者。

{"title":"Cambridge risk score, new hyperglycemia, and complications in surgical patients without diabetes","authors":"Hannah Lee , Phillip J. Hartfield , Abigail Thorgerson , Grant P. Sinson , Marjorie Wang , Carlos E. Mendez","doi":"10.1016/j.jdiacomp.2024.108926","DOIUrl":"10.1016/j.jdiacomp.2024.108926","url":null,"abstract":"<div><h3>Aims</h3><div>Our study examined the association between the Cambridge Risk Score (CRS), new hyperglycemia (NH), and complications in patients undergoing elective surgery.</div></div><div><h3>Methods</h3><div>In this retrospective cross-sectional study, adult surgical patients, without diabetes, with NH (blood glucose ≥140 mg/dL) were identified, and the CRS was calculated. We used univariate regression models to evaluate the relationship between CRS and NH with 30-day readmission, length of stay (LOS), and complications. Models were stratified by surgical specialty (cardiac/vascular, general, orthopedic, neurologic).</div></div><div><h3>Results</h3><div>Of 10,531 patients in the study, 24 % had NH. After adjusting for covariates, the CRS was associated with increased odds of complications [OR 2.09; 95%CI:1.69, 2.59] and NH [OR 1.95; 95%CI:1.66, 2.29]. NH was associated with increased odds of 30-day readmission [β 1.60; 95%CI:1.31, 1.96], and increased LOS [β 0.64; 95%CI:0.59, 0.68]. When stratified by surgery type, the CRS was associated with increased LOS in neurosurgery, decreased LOS in orthopedics, and increased odds of complications and NH in neurosurgery and orthopedics.</div></div><div><h3>Conclusion</h3><div>The CRS is associated with NH, complications, and LOS in patients undergoing elective neurosurgery, orthopedic surgery, and general surgery. This suggests that CRS may have potential to help identify surgical patients at high risk for NH and complications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108926"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contents/Barcode

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2025-01-01 DOI: 10.1016/S1056-8727(24)00263-0

引用次数: 0

Hepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways GLP-1模拟物在糖尿病环境中的肝脏作用：相关途径的机制综述。

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2025-01-01 DOI: 10.1016/j.jdiacomp.2024.108928

Habib Yaribeygi , Kiana Kashian , Kimia Imani Moghaddam , Sheida Rashmeh Karim , Narges Bagheri , Sercan Karav , Tannaz Jamialahmadi , Manfredi Rizzo , Amirhossein Sahebkar

Patients with diabetic are at a higher risk of developing hepatic disorders compared to non-diabetic individuals. This increased risk can be attributed to the diabetic environment, which triggers and exacerbates harmful pathways involved in both diabetic complications and hepatic disorders. Therefore, it is important to consider the use of antidiabetic agents that offer benefits beyond glycemic control and have positive effects on liver tissues. Glucagon-like peptide-1 (GLP-1) mimetics are a novel class of antidiabetic medications known for their potent blood sugar-lowering effects. Emerging evidence suggests that these drugs also have favorable effects on the liver. However, the precise effects and underlying mechanisms are not yet fully understood. In this review, we aim to provide a mechanistic perspective on the liver benefits of GLP-1 mimetics and outline the mediating mechanisms involved.

与非糖尿病患者相比，糖尿病患者发生肝脏疾病的风险更高。这种增加的风险可归因于糖尿病环境，它触发并加剧了与糖尿病并发症和肝脏疾病有关的有害途径。因此，考虑使用抗糖尿病药物是很重要的，这些药物不仅能控制血糖，还能对肝组织产生积极作用。胰高血糖素样肽-1 （GLP-1）模拟物是一类新型的抗糖尿病药物，以其有效的降血糖作用而闻名。新出现的证据表明，这些药物对肝脏也有有益的作用。然而，确切的影响和潜在的机制尚未完全了解。在这篇综述中，我们的目的是提供GLP-1模拟物的肝脏益处的机制观点，并概述所涉及的介导机制。

引用次数: 0

Slowly progressive subtype of childhood-onset type 1 diabetes as a high-risk factor for end-stage renal disease: A cohort study in Japan 儿童期发病的缓慢进展亚型1型糖尿病是终末期肾脏疾病的高危因素：日本的一项队列研究

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2024-11-28 DOI: 10.1016/j.jdiacomp.2024.108922

Hiroshi Yokomichi , Mie Mochizuki , Shigeru Suzuki , Yoshiya Ito , Tomoyuki Hotsubo , Nobuo Matsuura

Aim

To compare the incidence of end-stage renal disease (ESRD) between slowly progressive type 1 diabetes and acute-onset type 1 diabetes.

Methods

This cohort study enrolled all 521 patients with childhood-onset type 1 diabetes with the year of onset from 1959 to 1996 in Hokkaido Prefecture, Japan. We calculated the ESRD incidence rate per 100,000 person-years by sex, onset year, onset age, and type 1 diabetes subtype (slowly progressive or acute-onset). We also constructed a Kaplan–Meier curve for ESRD by these risk factors.

Results

The data of 391 patients were gathered, among whom 66 developed ESRD. The ESRD incidence rate per 100,000 person-years was 525 among all patients; 538 and 503 among women (n = 235) and men (n = 156); 893, 413, and 225 for onset year of 1959–1979 (n = 107), 1980–1989 (n = 201), and 1990–1996 (n = 83); 420 and 715 for onset before (n = 243) and after (n = 148) puberty; and 1388 and 432 for the slowly progressive (n = 41) and acute-onset (n = 350) subtypes, respectively. The Kaplan–Meier curve also indicated a significantly higher incidence of ESRD in slowly progressive than in acute-onset type 1 diabetes.

Conclusion

The incidence of ESRD was higher in slowly progressive than acute-onset type 1 diabetes.

目的比较慢进展型1型糖尿病与急性发作型1型糖尿病终末期肾病（ESRD）的发生率。方法本队列研究纳入了1959 - 1996年日本北海道地区521例儿童期发病的1型糖尿病患者。我们按性别、发病年份、发病年龄和1型糖尿病亚型（缓慢进展或急性发作）计算了每10万人年的ESRD发病率。我们还根据这些危险因素构建了ESRD的Kaplan-Meier曲线。结果共收集391例患者资料，其中66例发生ESRD。所有患者的ESRD发病率为每10万人年525例；女性（n = 235）和男性（n = 156）分别为538和503例；1959-1979年（n = 107）、1980-1989年（n = 201）和1990-1996年（n = 83）发病年份分别为893、413和225；青春期前（n = 243）和青春期后（n = 148）发病分别为420例和715例；缓慢进展亚型（n = 41）和急性发作亚型（n = 350）分别为1388例和432例。Kaplan-Meier曲线也显示缓慢进展型糖尿病的ESRD发生率明显高于急性发作型1型糖尿病。结论慢进展型糖尿病的ESRD发生率高于急性发作型糖尿病。

{"title":"Slowly progressive subtype of childhood-onset type 1 diabetes as a high-risk factor for end-stage renal disease: A cohort study in Japan","authors":"Hiroshi Yokomichi , Mie Mochizuki , Shigeru Suzuki , Yoshiya Ito , Tomoyuki Hotsubo , Nobuo Matsuura","doi":"10.1016/j.jdiacomp.2024.108922","DOIUrl":"10.1016/j.jdiacomp.2024.108922","url":null,"abstract":"<div><h3>Aim</h3><div>To compare the incidence of end-stage renal disease (ESRD) between slowly progressive type 1 diabetes and acute-onset type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cohort study enrolled all 521 patients with childhood-onset type 1 diabetes with the year of onset from 1959 to 1996 in Hokkaido Prefecture, Japan. We calculated the ESRD incidence rate per 100,000 person-years by sex, onset year, onset age, and type 1 diabetes subtype (slowly progressive or acute-onset). We also constructed a Kaplan–Meier curve for ESRD by these risk factors.</div></div><div><h3>Results</h3><div>The data of 391 patients were gathered, among whom 66 developed ESRD. The ESRD incidence rate per 100,000 person-years was 525 among all patients; 538 and 503 among women (<em>n</em> = 235) and men (<em>n</em> = 156); 893, 413, and 225 for onset year of 1959–1979 (<em>n</em> = 107), 1980–1989 (<em>n</em> = 201), and 1990–1996 (<em>n</em> = 83); 420 and 715 for onset before (<em>n</em> = 243) and after (<em>n</em> = 148) puberty; and 1388 and 432 for the slowly progressive (<em>n</em> = 41) and acute-onset (<em>n</em> = 350) subtypes, respectively. The Kaplan–Meier curve also indicated a significantly higher incidence of ESRD in slowly progressive than in acute-onset type 1 diabetes.</div></div><div><h3>Conclusion</h3><div>The incidence of ESRD was higher in slowly progressive than acute-onset type 1 diabetes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108922"},"PeriodicalIF":2.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic importance of baseline and changes in serum uric acid for macro/microvascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort 基线和血清尿酸变化对2型糖尿病患者大血管/微血管和死亡结局的预后重要性：里约热内卢de Janeiro 2型糖尿病队列

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2024-11-27 DOI: 10.1016/j.jdiacomp.2024.108921

Claudia R.L. Cardoso, Lucas da Silva Pereira, Nathalie C. Leite, Gil F. Salles

Aims

To investigate the associations between baseline/changes in serum uric acid (sUA) and the risks for cardiovascular/microvascular outcomes and mortality in a type 2 diabetes cohort.

Methods

Baseline sUA was measured in 685 individuals, and 463 had a second sUA measurement during follow-up; sUA was analyzed as a continuous variable and categorized into sex-specific tertile subgroups and low/high levels (>4.5 mg/dl women; >5.5 mg/dl men). The risks associated with baseline sUA and its changes were examined by Cox analyses for all outcomes.

Results

Median follow up was 10.7 years, there were 173 major cardiovascular events (MACEs), 268 all-cause deaths, 127 microalbuminuria, 104 renal failure, 160 retinopathy and 178 peripheral neuropathy outcomes. Baseline sUA was predictor of all outcomes, except all-cause mortality and retinopathy. In tertile and high/low sUA analyses, the hazard ratios (HRs) varied from 1.6 (microalbuminuria development) to 2.4 (MACEs; cardiovascular mortality). There was interaction with sex for MACEs, an increased risk was observed in women (HR: 2.6), but not in men (HR: 1.2). Changes in sUA were associated with the renal failure (HR: 2.4).

Conclusions

In a prospective cohort, high baseline sUA was a predictor of cardiovascular, renal and peripheral neuropathy. However, sUA changes were only predictor of renal failure.

目的研究2型糖尿病患者血清尿酸（sUA）基线/变化与心血管/微血管结局和死亡率风险之间的关系。方法对685例患者进行基线sUA测量，其中463例在随访期间进行了第二次sUA测量；将sUA作为连续变量进行分析，并将其分为性别特异性亚组和低/高水平(>；4.5 mg/dl女性；男性5.5毫克/分升)。所有结果的Cox分析检查了与基线sUA及其变化相关的风险。结果中位随访时间为10.7年，主要心血管事件（mace） 173例，全因死亡268例，微量白蛋白尿127例，肾功能衰竭104例，视网膜病变160例，周围神经病变178例。基线sUA是所有结果的预测因子，除了全因死亡率和视网膜病变。在分位数和高/低sUA分析中，风险比（hr）从1.6（微量白蛋白尿发展）到2.4 （mace）不等；心血管死亡率)。mace与性别有相互作用，在女性中观察到风险增加（HR: 2.6），但在男性中没有（HR: 1.2）。sUA的变化与肾功能衰竭有关（HR: 2.4）。结论在一项前瞻性队列研究中，高基线sUA是心血管、肾脏和周围神经病变的预测因子。然而，sUA变化仅是肾功能衰竭的预测因子。

{"title":"Prognostic importance of baseline and changes in serum uric acid for macro/microvascular and mortality outcomes in individuals with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort","authors":"Claudia R.L. Cardoso, Lucas da Silva Pereira, Nathalie C. Leite, Gil F. Salles","doi":"10.1016/j.jdiacomp.2024.108921","DOIUrl":"10.1016/j.jdiacomp.2024.108921","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the associations between baseline/changes in serum uric acid (sUA) and the risks for cardiovascular/microvascular outcomes and mortality in a type 2 diabetes cohort.</div></div><div><h3>Methods</h3><div>Baseline sUA was measured in 685 individuals, and 463 had a second sUA measurement during follow-up; sUA was analyzed as a continuous variable and categorized into sex-specific tertile subgroups and low/high levels (>4.5 mg/dl women; >5.5 mg/dl men). The risks associated with baseline sUA and its changes were examined by Cox analyses for all outcomes.</div></div><div><h3>Results</h3><div>Median follow up was 10.7 years, there were 173 major cardiovascular events (MACEs), 268 all-cause deaths, 127 microalbuminuria, 104 renal failure, 160 retinopathy and 178 peripheral neuropathy outcomes. Baseline sUA was predictor of all outcomes, except all-cause mortality and retinopathy. In tertile and high/low sUA analyses, the hazard ratios (HRs) varied from 1.6 (microalbuminuria development) to 2.4 (MACEs; cardiovascular mortality). There was interaction with sex for MACEs, an increased risk was observed in women (HR: 2.6), but not in men (HR: 1.2). Changes in sUA were associated with the renal failure (HR: 2.4).</div></div><div><h3>Conclusions</h3><div>In a prospective cohort, high baseline sUA was a predictor of cardiovascular, renal and peripheral neuropathy. However, sUA changes were only predictor of renal failure.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108921"},"PeriodicalIF":2.9,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142747985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contents/Barcode 内容/条形码

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2024-11-22 DOI: 10.1016/S1056-8727(24)00242-3

引用次数: 0

Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2 达帕格列净通过抑制SGLT-2下调高糖/高脂诱导的自噬，从而改善人脐静脉内皮细胞（HUVEC）的功能障碍

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2024-11-19 DOI: 10.1016/j.jdiacomp.2024.108907

Lijiahui Lin , Siyu Zhong , Ying Zhou , Jie Xia , Shanshan Deng , Tao Jiang , Aihua Jiang , Zhimei Huang , Jianping Wang

Objective

To investigate the effect of Dapagliflozin (Da) on the disorders of human umbilical vein endothelial cells (HUVECs) induced by high glucose and high fat (HG/HF).

Methods

Immunohistochemistry and immunofluorescence were used to detect the SGLT-2 expression in thoracic aortic tissues. After transfected with overexpressed plasmid SLC5A2, autophagy and cell functions of HUVECs were detected with the treatment of autophagy inhibitor 3-MA (5 mM). HUVECs were exposed to mannitol (MAN), glucose/palmitate (Hg/PA), and Hg/PA/Da for 24 h, and the proliferation of HUVECs was detected by CCK-8. The protein expression levels, endothelial cell functions (cell proliferation, migration, tubular formation, apoptosis, and autophagy) in endothelial cells were evaluated.

Results

The SGLT-2 expression was found in atherosclerotic human thoracic aorta tissues and HG/PA induced HUVECs (P < 0.05). After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05). After the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05). Moreover, the increased protein expression levels of autophagy and apoptosis in HG/PA induced HUVECs were also decreased by the treatment of Dapagliflozin (P < 0.05).

Conclusions

Dapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.

方法采用免疫组织化学和免疫荧光技术检测胸主动脉组织中SGLT-2的表达。转染过表达质粒 SLC5A2 后，用自噬抑制剂 3-MA（5 mM）检测 HUVEC 的自噬和细胞功能。HUVEC暴露于甘露醇（MAN）、葡萄糖/棕榈酸酯（Hg/PA）和Hg/PA/Da中24小时后，用CCK-8检测HUVEC的增殖。结果SGLT-2在动脉粥样硬化人胸主动脉组织和HG/PA诱导的HUVECs中均有表达（P< 0.05）。在 HUVECs 中过表达 SGLT-2 后，HUVECs 的增殖、迁移和小管形成能力受到抑制，自噬和细胞凋亡增加，3-MA 可逆转这些现象（P < 0.05）。加入葡萄糖钠协同转运体 2 抑制剂达帕格列净（Dapagliflozin）后，受 HG/PA 抑制的 HUVECs 增殖、小管形成、自噬、细胞凋亡和迁移能力均得到明显改善（P < 0.05）。结论Dapagliflozin可通过抑制SGLT-2下调自噬，改善高糖/高脂诱导的人脐静脉内皮细胞的功能障碍。

{"title":"Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2","authors":"Lijiahui Lin , Siyu Zhong , Ying Zhou , Jie Xia , Shanshan Deng , Tao Jiang , Aihua Jiang , Zhimei Huang , Jianping Wang","doi":"10.1016/j.jdiacomp.2024.108907","DOIUrl":"10.1016/j.jdiacomp.2024.108907","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the effect of Dapagliflozin (Da) on the disorders of human umbilical vein endothelial cells (HUVECs) induced by high glucose and high fat (HG/HF).</div></div><div><h3>Methods</h3><div>Immunohistochemistry and immunofluorescence were used to detect the SGLT-2 expression in thoracic aortic tissues. After transfected with overexpressed plasmid SLC5A2, autophagy and cell functions of HUVECs were detected with the treatment of autophagy inhibitor 3-MA (5 mM). HUVECs were exposed to mannitol (MAN), glucose/palmitate (Hg/PA), and Hg/PA/Da for 24 h, and the proliferation of HUVECs was detected by CCK-8. The protein expression levels, endothelial cell functions (cell proliferation, migration, tubular formation, apoptosis, and autophagy) in endothelial cells were evaluated.</div></div><div><h3>Results</h3><div>The SGLT-2 expression was found in atherosclerotic human thoracic aorta tissues and HG/PA induced HUVECs (<em>P</em> < 0.05). After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (<em>P</em> < 0.05). After the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (<em>P</em> < 0.05). Moreover, the increased protein expression levels of autophagy and apoptosis in HG/PA induced HUVECs were also decreased by the treatment of Dapagliflozin (<em>P</em> < 0.05).</div></div><div><h3>Conclusions</h3><div>Dapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 1","pages":"Article 108907"},"PeriodicalIF":2.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetic macular edema: Variations in observations with intensive treatment optimizing glycemia 糖尿病黄斑水肿：优化血糖强化治疗的观察结果变化。

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications

Pub Date : 2024-11-17 DOI: 10.1016/j.jdiacomp.2024.108909

Maria S. Varughese , Ananth U. Nayak

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of diabetes and its complications

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀